Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 11.50% | 59.58% | -84.48% | -152.39% | -127.70% |
| Gross Profit | -11.50% | -59.58% | 84.48% | 152.39% | 127.70% |
| SG&A Expenses | 39.35% | -2.42% | -30.98% | -46.09% | -51.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.75% | -35.39% | -52.20% | -46.22% | -37.57% |
| Operating Income | 24.75% | 35.39% | 52.20% | 46.22% | 37.57% |
| Income Before Tax | 24.28% | 39.93% | 50.66% | 42.82% | 31.78% |
| Income Tax Expenses | 178.57% | 110.00% | 550.00% | -210.34% | -172.41% |
| Earnings from Continuing Operations | 24.21% | 39.92% | 50.63% | 42.89% | 31.84% |
| Earnings from Discontinued Operations | 100.00% | 69.79% | 89.39% | 97.78% | 87.37% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.15% | 40.77% | 53.35% | 54.71% | 44.50% |
| EBIT | 24.75% | 35.39% | 52.20% | 46.22% | 37.57% |
| EBITDA | 72.51% | 59.99% | 51.43% | 45.43% | 37.33% |
| EPS Basic | 90.18% | 83.89% | 74.56% | 69.64% | 55.56% |
| Normalized Basic EPS | 88.22% | 81.95% | 72.96% | 65.07% | 48.18% |
| EPS Diluted | 90.18% | 83.88% | 74.56% | 69.66% | 55.58% |
| Normalized Diluted EPS | 88.22% | 81.95% | 72.96% | 65.07% | 48.18% |
| Average Basic Shares Outstanding | 805.39% | 554.07% | 256.08% | 98.03% | 31.12% |
| Average Diluted Shares Outstanding | 805.39% | 554.07% | 256.08% | 98.03% | 31.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |